Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
October 16th, 2009 Posted by: admin
Publication year: 2009<br><b>Source:</b> The American Journal of Cardiology, In Press, Corrected Proof, Available online 14 October 2009<br>Brett R., Cowan , Alistair A., Young , Craig, Anderson , Robert N., Doughty , Rungroj, Krittayaphong , …<br><br>The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease
Similar Posts:
- Telmisartan in High-Risk Cardiovascular Patients
- Are There Effects of Renin–Angiotensin System Antagonists Beyond Blood Pressure Control?
- Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases
- Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
- Renin–Angiotensin System Blockade and Cardiovascular and Renal Protection
- Age- and Gender-Related Differences in Quality of Care and Outcomes of Patients Hospitalized With Heart Failure (from OPTIMIZE-HF)
- Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease
- Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension
- Effect of Quinapril on In-Stent Restenosis and Relation to Plasma Apoptosis Signaling Molecules
- Angiotensin receptors in the eyes of arterial hypertensive rats